Associated tags: Inc., Medical tourism, Patient, Viatris, News, Court
Locations: NEW YORK, INDIA, UK, MINNESOTA, TAIWAN, ASIA, UKRAINE, FARMINGTON HILLS, MI, US, ENGLAND, SAN DIEGO, CA, NY, SYRIA, SEATTLE, WA, ATLANTA, GA, LOS ANGELES, LONDON, CHICAGO, PARIS, TEL AVIV, EUROPE, AMSTERDAM, CAMBODIA, RADNOR, PA, CAN, USA, READING, DE, WALL STREET, ALLSCHWIL, CH, LR, CANADA, JAPAN, WASHINGTON, HON, PENNSYLVANIA, UNITED STATES
PITTSBURGH, May 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada on Tuesday, May 14, 2024.
Key Points:
- PITTSBURGH, May 2, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the company will participate in the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada on Tuesday, May 14, 2024.
- Chief Financial Officer Doretta Mistras and Chief R&D Officer Philippe Martin will represent the company in a fireside chat scheduled at 10 a.m. PT / 1 p.m.
- Interested parties can access a live webcast of the event at investor.viatris.com .
- An archived version also will be available following the live event and can be accessed at the same location for a limited time.
Elevate,
World Health Organization,
Health,
Partnership,
Happiness,
Workplace,
Research,
Depression,
Rest,
Friends,
Mental health,
Hobby,
Workforce,
Caesars Entertainment,
Anxiety,
Sleep,
Organization,
Growth,
COVID-19,
Nursing Unmind is a leading provider of workplace mental health solutions designed by psychologists to help individuals understand and be proactive with their mental health and lead healthier, happier lives.
Key Points:
- Unmind is a leading provider of workplace mental health solutions designed by psychologists to help individuals understand and be proactive with their mental health and lead healthier, happier lives.
- "The mental wellbeing of our colleagues is extremely important and just one of the many reasons why Viatris introduced Elevate, our wellbeing program, in 2023 with the principles of health, purpose and growth," said Viatris' Chief People Officer Andrew Enrietti .
- Viatris' Elevate program has been built on three principles that help colleagues support their wellbeing:
Health – Nourishing mental and physical self.
- That is why Viatris is focused on the goal of providing all colleagues with wellbeing resources, including access to mental health tools and support.
PITTSBURGH, April 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets.
Key Points:
- PITTSBURGH, April 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets.
- Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m.
- ET on the same date to discuss the results.
- A replay of the webcast also will be available on the website.
Corinne,
Business administration,
Viatris,
Paris Descartes University,
Senior,
Patient,
Pharming,
Health,
Biotechnology,
COVID-19,
Growth,
Amgen,
Management PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today.
Key Points:
- PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today.
- Prior to joining Viatris, Le Goff was President and Chief Executive Officer of Imunon, a clinical-stage biotechnology company, where she led an organizational turnaround and rebranding effort.
- Prior to Imunon, Le Goff served as Chief Commercial Officer at Moderna, where she was responsible for building the commercial organization and key capabilities necessary to ensure global access to Moderna's COVID-19 vaccine.
- Le Goff said: "I am thrilled to join Viatris as the company embarks on its next exciting chapter.
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS).
Key Points:
- FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS).
- Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine Ophthalmic Solution 0.75%.
- Under the terms of this agreement, Ocuphire is eligible to receive regulatory and commercial milestones as well as royalties.
Class Action Lawsuit,
Professional Services,
Legal,
Claim,
Agreement,
Prejudice,
Action,
Defendant,
Summons,
Person,
Viatris,
CLASS,
ARE,
Settlement,
Court of Common Pleas,
Pfizer,
Court,
Hearing,
Law,
Generic drug YOUR RIGHTS MAY BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
Key Points:
- YOUR RIGHTS MAY BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
- A hearing will be held on June 12, 2024 at 1:00 p.m. Eastern Time, before the Hon.
- Please do not contact the Court, the Clerk’s office, Viatris, the other Defendants, or their counsel regarding this notice.
- All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to Lead Counsel or the Claims Administrator.
Glaucoma,
Agonist,
Rheumatoid arthritis,
Phenylephrine,
Diabetes,
Inflammation,
Patient,
Ageing,
American Optometric Association,
Eye injury,
American Academy,
Mydriasis,
United,
Viatris,
Eye,
Parasympatholytic,
Uveitis,
Lens,
Pupil,
Tropicamide,
FDA,
Cataract,
Diabetic retinopathy,
Food,
Pharmaceutical industry PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States.
Key Points:
- PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States.
- The onset of action of RYZUMVI generally occurs in 30 minutes.
- In the MIRA-2 trials' placebo group, 34% of patients were still dilated (had not returned to ≤ 0.2 mm of baseline pupil diameter) at 24 hours.
- To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.
Retrieved on:
Wednesday, March 27, 2024
Element,
Myocardial infarction,
FACC,
Interest,
AMI,
Growth,
Lupus,
Cardiology,
SPA,
Patient,
Columbia University,
NYU,
Faculty,
FAHA,
MBA,
FESC,
Heart failure,
MPH,
Safety,
OPUS,
FDA,
Autoimmune disease,
Food,
Hospital,
Pharmaceutical industry The focus of the event will be a discussion of its collaboration with Idorsia, Phase 3 assets selatogrel and cenerimod and key elements of the Company's pipeline.
Key Points:
- The focus of the event will be a discussion of its collaboration with Idorsia, Phase 3 assets selatogrel and cenerimod and key elements of the Company's pipeline.
- The collaboration with Idorsia is a great example of Viatris' strategy in action—adding two late-stage potential blockbuster assets, selatogrel and cenerimod—and connecting Idorsia's highly productive drug development team and innovation engine with Viatris' existing infrastructure and experience.
- The Company will review key elements of the collaboration including how Viatris can make a difference in the delivery of these assets.
- An archived version also will be available following the live event and can be accessed at the same location for a limited time.
Claim,
Agreement,
Prejudice,
Action,
Defendant,
Summons,
Person,
Fee,
Clerk,
Viatris,
ARE,
Settlement,
Counsel,
Court of Common Pleas,
Pfizer,
Court,
Hearing,
Law,
Generic drug your rights MAY be affected by a class action lawsuit pending in this court.
Key Points:
- your rights MAY be affected by a class action lawsuit pending in this court.
- A hearing will be held on June 12, 2024 at 1:00 p.m. Eastern Time, before the Hon.
- Please do not contact the Court, the Clerk's office, Viatris, the other Defendants, or their counsel regarding this notice.
- All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to Lead Counsel or the Claims Administrator.
Retrieved on:
Wednesday, February 28, 2024
Key Points:
- 53 LR
Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod.
- Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone payments, additional sales milestone payments and tiered royalties on annual net sales.
- Viatris and Idorsia will both contribute to the development costs for both programs.
- Combines Viatris’ financial strength and worldwide operational infrastructure with Idorsia’s proven, highly productive drug development team and innovative engine.
